Georgia CTSA Newsletter
|
Trouble viewing this email? View on the web.
| |
|  | 
Georgia CTSA
Weekly eRoundup
March 1, 2019
|
| |
| | | | | Day 1 of the 2nd Annual Georgia Clinical & Translational Science Conference kicked off with over 260 attendees and 100 poster presentations. Attendees came from all across the state including Augusta University, Emory University, Georgia State University, Georgia Institute of Technology, Mercer University, Morehouse School of Medicine, and University of Georgia (UGA), as well as BioCircuit Technologies, Centers for Disease Control, Children’s ... | | | | Read More | | |
|
| |
| | | | | Join Georgia Clinical & Translational Science Alliance colleagues at this 6th annual health services research symposium and networking opportunity. Oral and poster presentations will be selected from submitted abstracts. ... | | | | Read More | | |
|
| |
| | | | Georgia CTSA's Biostatistics, Epidemiology & Research Design (BERD) program is soliciting proposals to support novel methodological research in biostatistics, epidemiology, or health economics to advance clinical and translational research (CTR). Review criteria include: (i.) quantitative methodological research to fill gaps in CTR; (ii.) innovation; (iii.) feasibility; and (iv.) plans for dissemination and translation of results. Awardees are encouraged to disseminate any software developed in their research to CTSpedia, an online knowledge base for CTR, as well as other relevant publicly available software repositories. | | | | Read More | | |
| |
| | | | The SOM Imagine, Innovate and Impact (I3) Venture Awards solicit innovative research proposals to catalyze promising early-stage concepts with commercial potential that do not yet qualify for funding from external sources. The I3 Venture Research Awards aim to cultivate inventors, innovators, and entrepreneurs driven to solve medicine's challenges and create patient impact. In the current round, grants will be considered for: Proposals with the potential to shape, de-risk, or scale up a potential new drug or technology in medicine (diagnostic, therapeutic, device or software) in less than one year. If successful, the proposal would ready the project for the next stage of translation (not necessarily to market readiness). Particularly creative ideas, even without preliminary data, will be considered provided compelling impact, feasibility and commercial potential is demonstrated. Proposals due by 5:00pm on April 1st. | | | | Read More | | |
| |
| | | | The Center for AIDS Research at Emory University (CFAR) R03 mechanism (CFAR-03) is designed to help move CFAR faculty toward independent investigator status in HIV/AIDS research at the National Institutes of Health (NIH) by funding mentored research projects that will strengthen the due competitiveness of subsequent NIH applications in NIH/OAR high priority areas of HIV research. | | | | Read More | | |
| |
| | | | NCATS invites small businesses and academic researchers to apply for the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. Small businesses and research organizations involved in commercializing innovative medical technologies are encouraged to apply. NCATS is particularly interested in applications that address research areas relevant to any stage of translation, from target validation through pre-clinical and clinical evaluation, to intervention implementation and dissemination. | | | | Read More | | |
| |
| | | | With one in three people having a clinical stroke during their lifetime and dementia occurring in an estimated 30% of post-stroke patients, the public health impact is enormous. The purpose of this FOA is to determine the specific subsets of stroke events that cause (and do not cause) cognitive impairment and dementia in post-stroke populations in the United States, including in health disparities populations, and what additional clinical factors, as well as comorbidities including those along the AD/ADRD spectrum, may causally synergize with stroke to result in cognitive impairment and dementia outcomes. Applicants are encouraged to leverage existing resources for VCID, stroke and other dementia research. | | | | Read More | | |
| |
| | | | The purpose of this program is to support research activities that expand the knowledge base related to complex products and formulation development, analysis, and manufacturing control to advance risk-based quality assessment of new and generic drug products. We will also consider biological products relevant to CDER (e.g., monoclonal antibodies and therapeutic proteins) for this announcement. | | | | Read More | | |
| |
| | | | The purpose of this FOA is to support improved cancer immunotherapy research projects that reduce the incidence and/or severity of immune-related adverse events (irAEs) while retaining anti-tumor efficacy. Single investigators and/or multidisciplinary teams with expertise in mechanisms of cancer immunology, immune tolerance, irAEs, autoimmunity, and/or patient characterization and selection are encouraged to propose projects that utilize appropriate model systems, clinical samples, and expertise of these research communities. The specific objectives are to generate new ideas and approaches to better understand and thereby reduce the incidence and/or severity of irAEs resulting from cancer immunotherapy. | | | | Read More | | |
| |
| | | | The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for UG3/UH3 cooperative agreements to support the development of a publicly available core set(s) of COAs and their related endpoints for specific disease indications.
The UG3/UH3 Phase Innovation Award Cooperative Agreement involves 2 phases. The UG3 phase will provide funding for 1 to 2 years to conduct planning activities. The UH3 phase will provide funding for 3 to 4 years to projects that successfully complete the planning activities and reach the projected milestones set in the UG3 phase. UH3 phase awards will be awarded after administrative review of eligible UG3 phase awards that have met the scientific milestone and feasibility requirements necessary for UH3 phase implementation. | | | | Read More | | |
| |
| | | | The Clinical and Translational Science Award (CTSA) Program Collaborative Innovation Award (CCIA) supports collaborative research activities that develop innovative solutions that will improve the efficiency, quality and impact of turning laboratory, clinic and community observations into interventions that improve the health of individuals and the public. This funding opportunity announcement (FOA) will support investigators from three or more CTSA Program hub institutions (see below under Eligible Individuals) to either: 1) form new collaborations, or to 2) significantly expand the scientific scope of existing collaborations, or to 3) engage new collaborators in pre-existing collaborations to solve a translational science problem no one hub can solve alone, or disseminate a solution to a translational science problem developed at one hub to other hubs, in so doing testing its robustness to different hub environments and structures and adapting it for further dissemination outside the CTSA Program consortium if appropriate. | | | | Read More | | |
| |
| | | | The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. | | | | Read More | | |
| |
| | | | The Emory Master of Science in Clinical Research (MSCR) degree program, in the Laney Graduate School at Emory University, provides innovative didactic and mentored research training to those interested in pursuing a career in clinical and/or translational research. The MSCR degree is designed for predoctoral (medical students, PhD students or PharmD students), postdoctoral trainees (resident and fellow physicians or PhD postdocs), and junior faculty (physicians, PhD-level scientists or PharmDs). Contact Cheryl Sroka at 404-727-5096 or at csroka@emory.edu.
| | | | Read More | | |
| |
| | | | Scholarship applications are being accepted for the Summer Institute in Statistical Genetics (SISG). All current graduate students are eligible to apply for tuition waivers for up to three modules. Please note postdocs are not eligible for SISG scholarships. Scholarship applications are due by March 31 (11:59 p.m. PST). Award notifications will be emailed by Friday, April 12. | | | | Read More | | |
| |
| | | | As of September 1, the new Pediatric Institute is in effect. As part of that transition, Children's Healthcare and Emory developed a revised IRB reliance agreement for collaborative research (research in which both Children's and Emory are engaged). | | | | Read More | | |
| |
| | | | The Research Registry Toolkit is designed to support teams creating and managing research registries. Each section includes examples, best practices, and tools to guide conversations about research registry development and maintenance. | | | | Read More | | |
| |
| | | | The statistics research group directed by ISyE associate professor Yajun Mei, is now offering free consulting for data-analysis questions in the domain of bio-related initiatives on the GA Tech Campus, every Monday from 10:30am to 11:30am in Room 3317 of the Petit Building during the 2018 fall and 2019 spring semester, starting from Monday, October 1, 2018. | | | | Read More | | |
| |
| | | | A free weekly walk-in statistical consulting clinic for Morehouse School of Medicine faculty, staff, and students from 10:00 a.m.-noon in MRC Annex, Bldg. F, S-14 Conference Room. | | | | Read More | | |
| |
| | | | The NCATS ASPIRE Design Challenges are designed to advance innovative and catalytic approaches towards solving the opioid crisis by developing. A Specialized Platform for Innovative Research Exploration (ASPIRE) to aid in the discovery and development of novel and effective treatments, while at the same time making the process faster and more cost-effective. The NCATS ASPIRE Design Challenges are part of the of the NIH's Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to the national opioid public health crisis. Solutions must be submitted to Challenge.gov by NOON Eastern Time on May 31, 2019. | | | | Read More | | |
| |
| | | | MSM and the American Association for Cancer Research welcome you to learn more about cancer prevention, early detection, diagnosis, treatment and survivorship to better navigate the cancer journey for yourself or a loved one. An exhibit area for local and national cancer organizations to share their resources with attendees will also be available.
Contact: Jennifer Creighton-752-1177 | | | | Read More | | |
| |
| |  | | The Georgia CTSA recently partnered with the All of Us Research Program. All of Us is a health research program funded by the National Institutes of Health (NIH). Its goal is to help researchers better understand why people get sick or stay healthy. The mission of the All of Us Research Program is simple: to speed up health research and medical breakthroughs. To do this, All of Us is asking one million people from across the U.S. to share their health ... | | | | Read More | | |
| |
| | | | Learn about statewide core facilities and shared resources that can support your research. Socialize with core leaders, other core users, and vendors displaying their latest platforms. | | | | Read More | | |
| |
| | | | Join us for the Inaugural Symposium March 21, 2019. Noon. School of Medicine - RM 110 Richard Ransohoff. Third Rock Ventures and Visiting Scientist at Harvard Medical School. Dept. of Cell Biology CND-Sponsored Keynote Speaker.
| | | | Read More | | |
| |
| | | | Emory University Center for AIDS Research and the Emory Center for Health in Aging are co-hosting the 2019 national conference at the Courtyard by Marriott Atlanta Decatur Downtown/Emory. This year¿s conference theme is Special Populations Aging with HIV. The conference will open with a Pre-Conference Mentoring Workshop on April 10. The deadline for abstract and mentee application submissions has been extended to December 21. | | | | Read More | | |
| |
| | | | The SEMDA Medtech Conference is the premier medical technology forum fostering business and educational opportunities for the medtech industry, including medical devices, diagnostics, and digital health.After a record-breaking 2018, SEMDA IS BACK as the must attend event for industry wishing to do business in the southeast region. Join attendees from across the country for the premier medical technology forum in the southeast. | | | | Read More | | |
| |
| | | | The conference feature Dr. Gary Kaplan, Chairman and CEO of Virginia Mason Medical Center, and Dr. Nancy Currie-Gregg, Professor of Engineering Practice at Texas A&M University and former NASA astronaut. Poster registration deadline is April 8. | | | | Read More | | |
| |
| | | | Hosted by the Pediatric Research Alliance institutions of Emory University, Children's Healthcare of Atlanta, Georgia Tech and Morehouse School of Medicine. Limited number of travel awards for oral and poster presenters coming from more than 100 miles outside of metro Atlanta, based on merit and need. $40 registration fee is waived for students, residents, postdocs and fellows. | | | | Read More | | |
| |
| For more information on Georgia Clinical & Translational Science Alliance (Georgia CTSA), please visit
www.GeorgiaCTSA.org. Do you have news, seminars, or events of interest to clinical and translational researchers? Send them to
GeorgiaCTSA@emory.edu by noon on Thursday. To suggest subscribers or unsubscribe to the listserv please email
GeorgiaCTSA@emory.edu.
Please include the following citation in any publications resulting from direct or indirect Georgia CTSA support, "Supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR002378. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." KL2 Scholars should also list KL2TR002381 and TL1 Trainees should also list TL1TR002382. |
| |
|
